STOCK TITAN

[SCHEDULE 13D/A] Kronos Bio, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D




Comment for Type of Reporting Person:
Explanatory Note: This Amendment No. 3, which amends the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on November 27, 2023 and, as amended by Amendment No. 1 filed June 12, 2024 and Amendment No. 2 filed July 2, 2024 (as amended, the "Original Schedule 13D") filed on behalf of Norbert Bischofberger, Ph.D., Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994, Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020, Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020, Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020, Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020, (collectively, the "Reporting Persons") is being filed to report the sale of all of the common stock, $0.001 par value per share (the "Common Stock"), of Kronos Bio, Inc., a Delaware corporation (the "Issuer") by the Reporting Persons, as more specifically described below, resulting in the Reporting Persons ceasing to be the beneficial owners of at least five percent of the Common Stock. Capitalized terms used but not defined herein have the meanings given to such terms in the Original Schedule 13D.


SCHEDULE 13D


BISCHOFBERGER NORBERT W
Signature:/s/ Norbert Bischofberger, Ph.D.
Name/Title:Norbert Bischofberger, Ph.D.
Date:06/20/2025
Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994
Signature:/s/ Norbert Bischofberger, Ph.D.
Name/Title:Norbert Bischofberger, Ph.D., Trustee
Date:06/20/2025
Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020
Signature:/s/ Norbert Bischofberger, Ph.D.
Name/Title:Norbert Bischofberger, Ph.D., Trustee
Date:06/20/2025
Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020
Signature:/s/ Norbert Bischofberger, Ph.D.
Name/Title:Norbert Bischofberger, Ph.D., Trustee
Date:06/20/2025
Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020
Signature:/s/ Norbert Bischofberger, Ph.D.
Name/Title:Norbert Bischofberger, Ph.D., Trustee
Date:06/20/2025
Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020
Signature:/s/ Norbert Bischofberger, Ph.D.
Name/Title:Norbert Bischofberger, Ph.D., Trustee
Date:06/20/2025
Kronos Bio, Inc.

NASDAQ:KRON

KRON Rankings

KRON Latest News

KRON Latest SEC Filings

KRON Stock Data

53.96M
46.03M
24.27%
31.44%
1.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN MATEO